Global Gangrene Treatment Market, By Type (Dry Gangrene, Wet Gangrene, Internal Gangrene and Others), Therapy Type (Larval Debridement Therapy, Hyperbaric Oxygen Therapy and Others), Treatment Type (Medication, Amputation, Surgery and Others), Route of Administration (Oral, Injectable, Topical and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
Gangrene Treatment Market Analysis and Size
The gangrene treatment market is expected to witness significant growth during the forecast period. As per the World Health Organization (WHO), diabetes is a leading cause of blindness, stroke and lower limb amputation. In the year 2019, 1.5 million deaths were caused by diabetes. The risk of gas gangrene has increased as the incidence of extreme traumatic injury has increased, leading to the growth of the gangrene market. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of gangrene treatment market.
Data Bridge Market Research analyses a growth rate in the global gangrene treatment market in the forecast period 2022-2029. The expected CAGR of global gangrene treatment market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Gangrene Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Dry Gangrene, Wet Gangrene, Internal Gangrene and Others), Therapy Type (Larval Debridement Therapy, Hyperbaric Oxygen Therapy and Others), Treatment Type (Medication, Amputation, Surgery and Others), Route of Administration (Oral, Injectable, Topical and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Hainan Poly Co. Ltd (China), WOCKHARDT (India)
|
|
Market Opportunities
|
|
Market Definition
Gangrene is a type of condition wherein the body tissues die because of either serious bacterial infection or the lack of blood flow. The cause for the extreme loss of blood supply could be an injury, underlying illness or infection. This disease prevalence is rising and essential diagnostic procedures and treatments will boost the growth of the market.
Global Gangrene Treatment Market Dynamics
Drivers
- Increase in Smoking and Lifestyle Changes
Cigarette smoking is one of the leading causes of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.
- Growing Demand for Hospitals and Clinics
The demand for hospitals and clinics is rising due to the rising number of piriformis syndrome patients which increases the number of treatments in the hospitals & clinics. This is the primary driver expected to boost the market's growth during the forecast period.
Opportunities
- Increase in the prevalence of diabetes
As per the reports of International Diabetes Federation (IDF), the adult diabetes population is around 537 million in 2021, and this number is increasing to 643 million in 2030. Several factors such as obesity, unhealthy diet, and physical inactivity are increasing the cases of Type 1 and Type 2 diabetes cases. The increasing occurrence of diabetic patients are the indication of the growing usage of meglitinides.
- Increase in Healthcare Expenditure
As per the statistics by the WHO, the global per capita healthcare expenditure amounted for this market is USD 1,064.741 in the year 2017. The global healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. Thus, it creates much opportunity for the treatment of gangrene disease.
Restraints/Challenges
- High Cost of Gangrene Treatment
The high cost of treatment and the associated management is expected to act as a major limitation on the growth of the gangrene treatment medicines market.
- Unavailability of Appropriate Treatments
To treat conditions that are rare, many times, all treatments are not available, especially in the under-developed countries. The severe patient needs to be treated with advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.
This global gangrene treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gangrene treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Gangrene Treatment Market
Increasing transmission rates associated with previous COVID-19 strains and a reduction in vaccination effectiveness have made understanding the strain's impacts all the more important. Covid-19 sufferers are suffering from stomach pain, vomiting, loss of appetite, nausea, hearing loss, and joint pain. In the last two months, some patients have developed microthrombi, or minute blood clots, that have led the affected tissue to die and develop gangrene. As per the local media, doctors are also discovering clots increasing in blood veins that supply the intestines, causing patients to have stomach pain as their only symptom. Thus, COVID-19 had a major impact on the global gangrene treatment market.
Global Gangrene Treatment Market Scope
The gangrene treatment market is segmented on the basis of type, therapy type, treatment type, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Dry Gangrene
- Wet Gangrene
- Internal Gangrene
- Others
Therapy Type
- Larval Debridement Therapy
- Hyperbaric Oxygen Therapy
- Others
Treatment Type
- Medication
- Amputation
- Surgery
- Others
Route of Administration
- Oral
- Injectable
- Topical
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Gangrene Treatment Market Regional Analysis/Insights
The gangrene treatment market is analyzed and market size insights and trends are provided by type, therapy type, treatment type, end-user, and distribution channel as referenced above.
The major countries covered in the gangrene treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the sturdy occurrence of major key players.
Asia-Pacific is dominating the market due to the rise in the number of cases of gangrene affecting mouth, nose and lips.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Gangrene Treatment Market Share Analysis
The gangrene treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gangrene treatment market.
Key players operating in the global gangrene treatment market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Hainan Poly Co. Ltd (China)
- WOCKHARDT (India)
SKU-